Table 4.

Characteristics of the potential pediatric asthma cohort and final pediatric asthma cohorts identified by existing CPs (i.e., CAPriCORN, PheKB), and our proposed CP (i.e., COMPAC) within UFHealth IDR.

Characteristics	Potential Asthma (N = 128,132)	CAPriCORN (N = 27,827)	PheKB (N = 32,465)	COMPAC (N = 28,878)
Age, N (%)
2 ~ 5	51,670 (40.3)	12,626 (45.4)	15,415 (47.5)	12,708 (44.0)
6 ~ 12	38,005 (29.7)	9,513 (34.2)	10,578 (32.6)	10,104 (35.0)
13 ~ 18	33,003 (25.8)	5,164 (18.6)	5,876 (18.1)	5,460 (18.9)
Sex, N (%)
Male	67,412 (52.6)	1,5737 (56.6)	18,211 (56.1)	16,379 (56.7)
Female	60,717 (47.4)	12,089 (43.4)	14,253 (43.9)	12,498 (43.3)
Unknown	3 (0.0)	1 (0.0)	1 (0.0)	1 (0.0)
Race/Ethnicity, N (%)
NHW	62,123 (48.5)	10,431 (37.5)	12,572 (38.7)	10,923 (37.8)
NHB	39,481 (30.8)	12,017 (43.2)	13,494 (41.6)	12,382 (42.9)
Hispanic	12,709 (9.9)	2,727 (9.8)	3,218 (9.9)	2,843 (9.8)
Other	4,873 (3.8)	905 (3.3)	1,086 (3.3)	933 (3.2)
Comorbidities, N (%)
Cough	29,673 (23.2)	13,636 (49.0)	15,446 (47.6)	13,425 (46.5)
Fever, unspecified	27,403 (21.4)	10,150 (36.5)	11,733 (36.1)	9,945 (34.4)
Acute upper respiratory infection, unspecified	25,095 (19.6)	9,162 (32.9)	10,723 (33.0)	8,826 (30.6)
Asthma, unspecified type, unspecified	20,992 (16.4)	14,354 (51.6)	14,500 (44.7)	14,299 (49.5)
Acute upper respiratory infections of unspecified site	16,810 (13.1)	7,623 (27.4)	8,426 (26.0)	7,517 (26.0)
Prescriptions, N (%)
amoxicillin (AMOXIL) 400 MG/5ML suspension	8,429 (6.6)	3,792 (13.6)	4,275 (13.2)	3,725 (12.9)
albuterol (PROVENTIL) (2.5 MG/3ML) 0.083% nebulizer solution 2.5 mg	8,054 (6.3)	5,704 (20.5)	6,127 (18.9)	5,616 (19.5)
fluticasone (FLONASE) 50 MCG/ACT Nasal Suspension	7,667 (6.0)	3,739 (13.4)	4,155 (12.8)	3,709 (12.8)
albuterol (PROAIR HFA;VENTOLIN HFA) 108 (90 BASE) MCG/ACT inhaler	7,470 (5.8)	5,539 (19.9)	5,755 (17.7)	5,566 (19.3)
amoxicillin (AMOXIL) 400 MG/5ML Suspension Reconstituted	6,980 (5.5)	2,869 (10.3)	3,348 (10.3)	2,794 (9.7)